Stefano Palcic

Stefano Palcic

Auto-generated profile, based on publicly available information

Stefano Palcic

Farmaceutica Territoriale, Azienda Sanitaria Universitaria Integrata Giuliano-Isontina (ASUGI), 34142 Trieste, Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
PAPaola Anello
Paola Anello
GBGiacomo Berti
Giacomo Berti
EMEdoardo Miotto
Edoardo Miotto
UGUmberto Gallo
Umberto Gallo
SPSTEFANO PALCIC
STEFANO PALCIC
AGARCO Working Group
ARCO Working Group
National and international frameworks provide strategic direction for antimicrobial stewardship (AMS), while their translation into operational practice remains inconsistent. Building on ARCO Step I findings, this study aimed to establish an interregional, multidisciplinary consensus on sustainable AMS implementation strategies across hospital and community settings in Northeastern Italy. A modified Delphi methodology engaged 33 interdisciplinary professionals from Northeastern Italy. Eighteen operational statements across three domains (Governance, Hospital AMS, Community AMS) underwent two quantitative scoring rounds (relevance and feasibility; 1–10 scale) separated by a structured in-person workshop with thematic round-table discussions. Consensus threshold was defined as median score ≥ 8.0; high-priority statements required combined score ≥ 8.5. All 18 statements achieved consensus for relevance, whereas 12 statements achieved consensus for feasibility. Post-discussion median scores feasibility showed a numerically larger increase for feasibility (Δ +0.78) compared to relevance (Δ +0.44), indicating that structured deliberation reduced perceived implementation barriers. Furthermore, 14 statements were classified as high-priority. Qualitative analysis identified key enablers (CEO performance mandates, multidisciplinary teams, standardized indicators) and barriers (digital infrastructure gaps, resource constraints). The participatory approach helped translate strategic policy into a set of practice-oriented recommendations, offering a potentially transferable model for regional health authorities implementing AMR action plans, pending evaluation of actual implementation.

5 December 2022 in Global and Regional Health Technology Assessment
Verified
Journal Article
Open access
PDF file
AMAnna Maria Marata
Anna Maria Marata
WMWalter Marrocco
Walter Marrocco
EAEmanuela Arcangeli
Emanuela Arcangeli
MBMattia Battistini
Mattia Battistini
GBGiuliano Buzzetti
Giuliano Buzzetti
ECElisa Crovato
Elisa Crovato
This document illustrates the results of the work of two interdisciplinary and multistakeholder panels (researchers, public institutions, and industry representatives) on drug territorialization and digitalization, organized as part of a residential seminar held on 30 September and 1st October 2021. Arising from some considerations about the demand for health and the provisions of the National Recovery and Resilience Plan (PNRR), the discussion touched various aspects of managing the transition from current to future management models. The importance of identifying criteria for prioritizing interventions in the area emerged: different methods of drug delivery, scientific information and measurement, re-evaluation of pathologies that can be managed in this area. Finally, the role of digitization within this change was explored. The opinions provided by the experts move towards making the most of the opportunities arising from PNRR, in terms of investments in healthcare and data application, with a view to improve health system efficiency, patient care and related outcomes.

4 March 2026 in Global and Regional Health Technology Assessment
Verified
Journal Article
Open access
GBGiacomo Matteo Bruno
Giacomo Matteo Bruno
MVMaria Chiara Valentino
Maria Chiara Valentino
SBStefano Buda
Stefano Buda
APArrigo Paciello
Arrigo Paciello
SPSTEFANO PALCIC
STEFANO PALCIC
GCGiorgio Lorenzo Colombo
Giorgio Lorenzo Colombo
Introduction: Type 2 diabetes mellitus (T2DM) is a common chronic disease with management, associated with cardiovascular and renal comorbidities. In January 2022, AIFA Note 100 extended prescribing authority for innovative antidiabetic drugs (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors) to General Practitioners, influencing treatment patterns and management of high-risk patients.Methods: A retrospective observational analysis used administrative data from two Local Health Authorities in Italy, comparing three cohorts: Pre-COVID (2018), COVID (2020-2021), and Post-Note 100 (February 1, 2022 to January 31, 2023). Adults (≥18 years) with at least one prescription of non-insulin glucose-lowering drugs (ATC A10B) were included. Profiles were described, focusing on acarbose, DPP-4 inhibitors, metformin, pioglitazone, SGLT-2 inhibitors, GLP-1 receptor agonists, and sulfonylureas. Clinical characteristics included comorbidities, heart failure, hypertension, and chronic kidney disease. Healthcare costs (pharmaceuticals, outpatient specialist care, and hospitalizations) were analyzed.Results: Over 140,000 subjects were included. In the Post–Note 100 phase, GLP-1 receptor agonists and SGLT-2 inhibitors increased among new users (GLP-1 receptor agonists: 1.2% to 9.3%; SGLT-2 inhibitors: 2.6% to 14.1%) and among prevalent users, with a reduction in sulfonylureas and a decline in metformin monotherapy. Among patients with ≥ 2 comorbidities, SGLT-2 inhibitors became the most prescribed class. Use rose in heart failure, while both GLP-1 receptor agonists and SGLT-2 inhibitors increased in chronic kidney disease.Conclusions: Expansion of prescribing eligibility introduced by AIFA Note 100 led to a shift toward innovative therapies, aligning prescribing with guidelines, particularly in comorbid patients. Real-world data highlight the impact and support the evaluation of long-term outcomes.